Evaluation of the Reveal ® rapid AST system to assess the susceptibility of Pseudomonas aeruginosa from blood cultures
This study was set up to assess the performance of the Reveal ® rapid AST system to determine the drug susceptibility ofPseudomonas aeruginosa strains directly from blood cultures. Two hundred fully sequenced clinicalP. aeruginosa strains were selected for the evaluation, of which 26.5% (n = 53) produced transferable β-lactamases, and 2.0 to 33.0% had susceptibility levels close to the EUCAST 2021 breakpoints of 11 commonly used antipseudomonal antibiotics. The Reveal® AST system was run with a commercial MIC microplate designed for fast-growing Gram-negative bacilli (Microscan Neg MDR MIC 1), and was compared to the manually operated GN6F MIC microdilution panel from Thermo Fisher, as a comparator method. The Reveal® AST system provided MIC results for the 11 antipseudomonal antibiotics tested within a mean time to result of 6 h 22 min. By comparison with the GN6F pan el, the overall rates of categorical agreement (CA), very major errors (VME), major errors (ME), and minor errors (mE for meropenem only) were 96.1%, 1.6%, 4.2%, and 0.6%, respectively. The Specific Reveal® AST system appears to be a reliable and fast technology to determine the susceptibility ofP. aeruginosa to antibiotics, including those with resistance levels near categorical breakpoints, directly from blood cultures.